title: Effect of magnesium on functional outcome and paraclinical parameters of patients undergoing supratentorial craniotomy for brain tumors: a randomized controlled trial.
abstract: BACKGROUND
  Several studies have demonstrated that magnesium (Mg) plays an important role in the prevention and treatment of central nervous system (CNS) insults. In this study, we tested the effect of intravenous magnesium sulfate (MgSO4) on the outcome of patients with brain tumors who underwent craniotomy. The outcome was defined clinically as the Barthel index score and paraclinically as blood levels of NSE (neuron-specific enloase) and S100Β protein.
  
  
  METHODS
  Sixty patients were randomly divided into two groups of 30 patients: the treatment and control groups. In the treatment group, 5 g of MgSO4 in normal saline was infused in 6 h 2 days before surgery, and the same dosage was repeated the day before and during surgery. The control group received placebo. Serum S100Β and NSE concentrations were measured at baseline before administration of magnesium, before surgery, and on the 2nd postoperative day. The Barthel index score was evaluated and registered before surgery, 3, and 6 months after the operation.
  
  
  RESULTS
  The study results showed a significant change in S100Β protein levels before and after surgery (p < 0.05), but we could not find similar results for NSE protein and the Barthel index score. There was a correlation between NSE protein and the Barthel index.
  
  
  CONCLUSIONS
  The results of this study revealed that administration of intravenous MgSO4 before and during surgery is safe and effective in reducing S100B protein levels in patients undergoing supratentorial craniotomy for brain tumors. Further studies to elucidate the pathophysiology of brain injuries and role of magnesium are warranted.
authors.affiliation: Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, 16 Azar Ave., Enghelab Sq., P.O. Box. 14155-6451, Tehran, Iran.
authors.forename: Bahador
authors.initials: B
authors.lastname: Mirrahimi
authors.forename: Abolghasem
authors.initials: A
authors.lastname: Mortazavi
authors.forename: Mohsen
authors.initials: M
authors.lastname: Nouri
authors.forename: Ebrahim
authors.initials: E
authors.lastname: Ketabchi
authors.forename: Abass
authors.initials: A
authors.lastname: Amirjamshidi
authors.forename: Asieh
authors.initials: A
authors.lastname: Ashouri
authors.forename: Mohammadreza
authors.initials: M
authors.lastname: Khajavi
authors.forename: Mojtaba
authors.initials: M
authors.lastname: Mojtahedzadeh
mesh_terms: D000328:Adult; D001930:Brain Injuries / Q000209:etiology / Q000517:prevention & control*; D001932:Brain Neoplasms / Q000097:blood / Q000601:surgery*; D003399:Craniotomy / Q000009:adverse effects* / Q000379:methods; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008278:Magnesium Sulfate / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010751:Phosphopyruvate Hydratase / Q000097:blood; D064568:S100 Calcium Binding Protein beta Subunit / Q000097:blood; D016896:Treatment Outcome
chemical_list: D064568:S100 Calcium Binding Protein beta Subunit; D008278:Magnesium Sulfate; D010751:Phosphopyruvate Hydratase